Science ❯ Biotechnology ❯ Drug Research ❯ Oncology

Obesity Treatments

Pfizer Tops Q4 Estimates but Posts Loss on $4.4 Billion Charge, Reaffirms 2026 Outlook

Management reiterates a flat 2026 outlook centered on cost cuts, obesity programs, pivotal trials.